Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zaizao Shengxue Capsules (再造生血胶囊) is a Traditional Chinese Medicine (TCM) developed and manufactured by Changshu Leiyunshang Pharmaceutical. It is approved in China for the treatment of various hematological disorders, including aplastic anemia, iron deficiency anemia, leukopenia, and thrombocytopenia. The formulation is composed of multiple herbal extracts, such as Rehmannia glutinosa, Angelica sinensis, and Astragalus membranaceus, which are traditionally used to tonify the liver and kidney, nourish the blood, and strengthen the spleen. Mechanistically, it is believed to stimulate hematopoietic function in the bone marrow and improve the hematopoietic microenvironment, thereby increasing the production of red blood cells, white blood cells, and platelets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zaizao Shengxue Capsules.